Previous 10 | Next 10 |
Buying stocks in a bear market necessitates courage, as you need to overcome your fear. Conquering your fear to purchase during a down cycle usually leads to outsized returns. Iovance Biotherapeutics is a fundamentally robust stock that is experiencing a decline. That makes it an idea...
Multiple investment houses cut PPDFollowing yesterday's announcement that Thermo Fisher Scientific (TMO) would spend $17B to acquire PPD (PPD), several investment houses, including Truist, Deutsche Bank, and Baird, have cut PPD shares to sell.Truist analyst Sandy Draper cut PPD shares to hold...
Mer Telemanagement Solutions Ltd. MTSL +91% on announcing merger with Sharplink.General Finance Corporation GFN +55% as United Rentals to buy the company for ~$996.0M.China Recycling Energy Corporation (CREG) +16%.Iovance Biotherapeutics (IOVA) +10%.StoneMor (STON) +9%.111...
Iovance Biotherapeutics (IOVA) announces data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma. Data highlights as of the December 14, 2020 data cut date are as follows:Lifileucel showed a 36.4% overall response rate (4.5% complete responses and 31.8% partial responses)....
Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA...
Achilles Therapeutics has filed proposed terms for a $176 million U.S. IPO. The firm is developing treatment candidates for various cancers. ACHL won't have data readout until the second half of 2022 for its Phase 1 safety trials, so the IPO may be more suited to institutional inv...
Today, we revisit oncology concern Iovance Biotherapeutics for the first time in years after a recent dip in its share price. The company appears to be building a leadership position in treating solid tumors and its first BLA submission is on the horizon. A full analysis follows i...
Iovance Biotherapeutics (IOVA) announces the appointment of Igor Bilinsky as the company's Chief Operating Officer.Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.Most recently Bilinsky ...
SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today....
Instil Bio has filed terms for its $250 million IPO. The firm is advancing autologous TIL treatment candidates for melanoma and other solid tumor cancers. TIL has produced intriguing early efficacy results but the IPO is priced far above the normal life science IPO range, so I'll ...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 05:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $10.00 for IOVA on 2024-07-29 02:11:00. The adjusted price target was set to $10.00. At the time of the announcement, IOVA was trading at $9.25. The overall price target consensus is at $...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...